Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Identifieur interne : 001956 ( Istex/Corpus ); précédent : 001955; suivant : 001957Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Auteurs : S.-E. Al-Batran ; J. T. Hartmann ; R. Hofheinz ; N. Homann ; V. Rethwisch ; S. Probst ; J. Stoehlmacher ; M. R. Clemens ; R. Mahlberg ; M. Fritz ; G. Seipelt ; M. Sievert ; C. Pauligk ; A. Atmaca ; E. JgerSource :
- Annals of Oncology [ 0923-7534 ] ; 2008-07-31.
Abstract
Background: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients and methods: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-h infusion in combination with docetaxel 50 mg/m2 (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered. Results: Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 2976) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only. Conclusions: Biweekly FLOT is active and has a favorable safety profile.
Url:
DOI: 10.1093/annonc/mdn403
Links to Exploration step
ISTEX:DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title><author><name sortKey="Al Batran, S E" sort="Al Batran, S E" uniqKey="Al Batran S" first="S.-E." last="Al-Batran">S.-E. Al-Batran</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: albatran@aol.com</mods:affiliation></affiliation></author><author><name sortKey="Hartmann, J T" sort="Hartmann, J T" uniqKey="Hartmann J" first="J. T." last="Hartmann">J. T. Hartmann</name><affiliation><mods:affiliation>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</mods:affiliation></affiliation></author><author><name sortKey="Hofheinz, R" sort="Hofheinz, R" uniqKey="Hofheinz R" first="R." last="Hofheinz">R. Hofheinz</name><affiliation><mods:affiliation>Department of Medicine III, Universittsklinikum Mannheim</mods:affiliation></affiliation></author><author><name sortKey="Homann, N" sort="Homann, N" uniqKey="Homann N" first="N." last="Homann">N. Homann</name><affiliation><mods:affiliation>Department of Medicine I, University of Lbeck</mods:affiliation></affiliation></author><author><name sortKey="Rethwisch, V" sort="Rethwisch, V" uniqKey="Rethwisch V" first="V." last="Rethwisch">V. Rethwisch</name><affiliation><mods:affiliation>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</mods:affiliation></affiliation></author><author><name sortKey="Probst, S" sort="Probst, S" uniqKey="Probst S" first="S." last="Probst">S. Probst</name><affiliation><mods:affiliation>Department of Hematology and Oncology, Stdtische Kliniken, Bielefeld</mods:affiliation></affiliation></author><author><name sortKey="Stoehlmacher, J" sort="Stoehlmacher, J" uniqKey="Stoehlmacher J" first="J." last="Stoehlmacher">J. Stoehlmacher</name><affiliation><mods:affiliation>Department of Internal Medicine I, Universittsklinikum Carl Gustav Carus, Dresden</mods:affiliation></affiliation></author><author><name sortKey="Clemens, M R" sort="Clemens, M R" uniqKey="Clemens M" first="M. R." last="Clemens">M. R. Clemens</name><affiliation><mods:affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</mods:affiliation></affiliation></author><author><name sortKey="Mahlberg, R" sort="Mahlberg, R" uniqKey="Mahlberg R" first="R." last="Mahlberg">R. Mahlberg</name><affiliation><mods:affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</mods:affiliation></affiliation></author><author><name sortKey="Fritz, M" sort="Fritz, M" uniqKey="Fritz M" first="M." last="Fritz">M. Fritz</name><affiliation><mods:affiliation>Krankenhaus Bad Cannstatt, Stuttgart</mods:affiliation></affiliation></author><author><name sortKey="Seipelt, G" sort="Seipelt, G" uniqKey="Seipelt G" first="G." last="Seipelt">G. Seipelt</name><affiliation><mods:affiliation>Gemeinschaftspraxis fr Hmatologie und Internistische Onkologie, Bad Soden</mods:affiliation></affiliation></author><author><name sortKey="Sievert, M" sort="Sievert, M" uniqKey="Sievert M" first="M." last="Sievert">M. Sievert</name><affiliation><mods:affiliation>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Pauligk, C" sort="Pauligk, C" uniqKey="Pauligk C" first="C." last="Pauligk">C. Pauligk</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author><author><name sortKey="Atmaca, A" sort="Atmaca, A" uniqKey="Atmaca A" first="A." last="Atmaca">A. Atmaca</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author><author><name sortKey="Jger, E" sort="Jger, E" uniqKey="Jger E" first="E." last="Jger">E. Jger</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1093/annonc/mdn403</idno><idno type="url">https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001956</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001956</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title><author><name sortKey="Al Batran, S E" sort="Al Batran, S E" uniqKey="Al Batran S" first="S.-E." last="Al-Batran">S.-E. Al-Batran</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: albatran@aol.com</mods:affiliation></affiliation></author><author><name sortKey="Hartmann, J T" sort="Hartmann, J T" uniqKey="Hartmann J" first="J. T." last="Hartmann">J. T. Hartmann</name><affiliation><mods:affiliation>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</mods:affiliation></affiliation></author><author><name sortKey="Hofheinz, R" sort="Hofheinz, R" uniqKey="Hofheinz R" first="R." last="Hofheinz">R. Hofheinz</name><affiliation><mods:affiliation>Department of Medicine III, Universittsklinikum Mannheim</mods:affiliation></affiliation></author><author><name sortKey="Homann, N" sort="Homann, N" uniqKey="Homann N" first="N." last="Homann">N. Homann</name><affiliation><mods:affiliation>Department of Medicine I, University of Lbeck</mods:affiliation></affiliation></author><author><name sortKey="Rethwisch, V" sort="Rethwisch, V" uniqKey="Rethwisch V" first="V." last="Rethwisch">V. Rethwisch</name><affiliation><mods:affiliation>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</mods:affiliation></affiliation></author><author><name sortKey="Probst, S" sort="Probst, S" uniqKey="Probst S" first="S." last="Probst">S. Probst</name><affiliation><mods:affiliation>Department of Hematology and Oncology, Stdtische Kliniken, Bielefeld</mods:affiliation></affiliation></author><author><name sortKey="Stoehlmacher, J" sort="Stoehlmacher, J" uniqKey="Stoehlmacher J" first="J." last="Stoehlmacher">J. Stoehlmacher</name><affiliation><mods:affiliation>Department of Internal Medicine I, Universittsklinikum Carl Gustav Carus, Dresden</mods:affiliation></affiliation></author><author><name sortKey="Clemens, M R" sort="Clemens, M R" uniqKey="Clemens M" first="M. R." last="Clemens">M. R. Clemens</name><affiliation><mods:affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</mods:affiliation></affiliation></author><author><name sortKey="Mahlberg, R" sort="Mahlberg, R" uniqKey="Mahlberg R" first="R." last="Mahlberg">R. Mahlberg</name><affiliation><mods:affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</mods:affiliation></affiliation></author><author><name sortKey="Fritz, M" sort="Fritz, M" uniqKey="Fritz M" first="M." last="Fritz">M. Fritz</name><affiliation><mods:affiliation>Krankenhaus Bad Cannstatt, Stuttgart</mods:affiliation></affiliation></author><author><name sortKey="Seipelt, G" sort="Seipelt, G" uniqKey="Seipelt G" first="G." last="Seipelt">G. Seipelt</name><affiliation><mods:affiliation>Gemeinschaftspraxis fr Hmatologie und Internistische Onkologie, Bad Soden</mods:affiliation></affiliation></author><author><name sortKey="Sievert, M" sort="Sievert, M" uniqKey="Sievert M" first="M." last="Sievert">M. Sievert</name><affiliation><mods:affiliation>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Pauligk, C" sort="Pauligk, C" uniqKey="Pauligk C" first="C." last="Pauligk">C. Pauligk</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author><author><name sortKey="Atmaca, A" sort="Atmaca, A" uniqKey="Atmaca A" first="A." last="Atmaca">A. Atmaca</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author><author><name sortKey="Jger, E" sort="Jger, E" uniqKey="Jger E" first="E." last="Jger">E. Jger</name><affiliation><mods:affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2008-07-31">2008-07-31</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1882">1882</biblScope><biblScope unit="page" to="1887">1887</biblScope></imprint><idno type="ISSN">0923-7534</idno></series><idno type="istex">DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0</idno><idno type="DOI">10.1093/annonc/mdn403</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients and methods: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-h infusion in combination with docetaxel 50 mg/m2 (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered. Results: Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 2976) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only. Conclusions: Biweekly FLOT is active and has a favorable safety profile.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>S.-E. Al-Batran</name><affiliations><json:string>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</json:string><json:string>E-mail: albatran@aol.com</json:string></affiliations></json:item><json:item><name>J. T. Hartmann</name><affiliations><json:string>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</json:string></affiliations></json:item><json:item><name>R. Hofheinz</name><affiliations><json:string>Department of Medicine III, Universittsklinikum Mannheim</json:string></affiliations></json:item><json:item><name>N. Homann</name><affiliations><json:string>Department of Medicine I, University of Lbeck</json:string></affiliations></json:item><json:item><name>V. Rethwisch</name><affiliations><json:string>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</json:string></affiliations></json:item><json:item><name>S. Probst</name><affiliations><json:string>Department of Hematology and Oncology, Stdtische Kliniken, Bielefeld</json:string></affiliations></json:item><json:item><name>J. Stoehlmacher</name><affiliations><json:string>Department of Internal Medicine I, Universittsklinikum Carl Gustav Carus, Dresden</json:string></affiliations></json:item><json:item><name>M. R. Clemens</name><affiliations><json:string>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</json:string></affiliations></json:item><json:item><name>R. Mahlberg</name><affiliations><json:string>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</json:string></affiliations></json:item><json:item><name>M. Fritz</name><affiliations><json:string>Krankenhaus Bad Cannstatt, Stuttgart</json:string></affiliations></json:item><json:item><name>G. Seipelt</name><affiliations><json:string>Gemeinschaftspraxis fr Hmatologie und Internistische Onkologie, Bad Soden</json:string></affiliations></json:item><json:item><name>M. Sievert</name><affiliations><json:string>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</json:string></affiliations></json:item><json:item><name>C. Pauligk</name><affiliations><json:string>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</json:string></affiliations></json:item><json:item><name>A. Atmaca</name><affiliations><json:string>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</json:string></affiliations></json:item><json:item><name>E. Jger</name><affiliations><json:string>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</json:string></affiliations></json:item></author><subject><json:item><value>original articles</value></json:item><json:item><value>docetaxel</value></json:item><json:item><value>esophageal</value></json:item><json:item><value>FLOT</value></json:item><json:item><value>gastric</value></json:item><json:item><value>oxaliplatin</value></json:item></subject><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Background: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients and methods: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-h infusion in combination with docetaxel 50 mg/m2 (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered. Results: Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 2976) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only. Conclusions: Biweekly FLOT is active and has a favorable safety profile.</abstract><qualityIndicators><score>7.998</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 791 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1415</abstractCharCount><pdfWordCount>3562</pdfWordCount><pdfCharCount>23998</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>203</abstractWordCount></qualityIndicators><title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title><refBibs><json:item><author><json:item><name>B Glimelius</name></json:item><json:item><name>K Ekstrom</name></json:item><json:item><name>K Hoffman</name></json:item></author><host><volume>8</volume><pages><last>168</last><first>163</first></pages><author></author><title>Ann Oncol</title><publicationDate>1997</publicationDate></host><title>Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</title><publicationDate>1997</publicationDate></json:item><json:item><author><json:item><name>T Foukakis</name></json:item><json:item><name>L Lundell</name></json:item><json:item><name>M Gubanski</name></json:item></author><host><volume>46</volume><pages><last>285</last><first>277</first></pages><author></author><title>Acta Oncol</title><publicationDate>2007</publicationDate></host><title>Advances in the treatment of patients with gastric adenocarcinoma</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>E Van Cutsem</name></json:item><json:item><name>Vm Moiseyenko</name></json:item><json:item><name>S Tjulandin</name></json:item></author><host><volume>24</volume><pages><last>4997</last><first>4991</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2006</publicationDate></host><title>Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group</title><publicationDate>2006</publicationDate></json:item><json:item><author><json:item><name>Ja Ajani</name></json:item><json:item><name>Vm Moiseyenko</name></json:item><json:item><name>S Tjulandin</name></json:item></author><host><volume>25</volume><pages><last>3216</last><first>3210</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2007</publicationDate></host><title>Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>Ja Ajani</name></json:item><json:item><name>Vm Moiseyenko</name></json:item><json:item><name>S Tjulandin</name></json:item></author><host><volume>25</volume><pages><last>3209</last><first>3205</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2007</publicationDate></host><title>Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>D Cunningham</name></json:item><json:item><name>N Starling</name></json:item><json:item><name>S Rao</name></json:item></author><host><volume>358</volume><pages><last>46</last><first>36</first></pages><author></author><title>N Engl J Med</title><publicationDate>2008</publicationDate></host><title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</title><publicationDate>2008</publicationDate></json:item><json:item><author><json:item><name>S Al-Batran</name></json:item><json:item><name>J Hartmann</name></json:item><json:item><name>S Probst</name></json:item></author><host><volume>26</volume><pages><last>1442</last><first>1435</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2008</publicationDate></host><title>Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie</title><publicationDate>2008</publicationDate></json:item><json:item><author><json:item><name>Se Al-Batran</name></json:item><json:item><name>A Atmaca</name></json:item><json:item><name>S Hegewisch-Becker</name></json:item></author><host><volume>22</volume><pages><last>663</last><first>658</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2004</publicationDate></host><title>Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer</title><publicationDate>2004</publicationDate></json:item><json:item><author><json:item><name>Se Al-Batran</name></json:item><json:item><name>A Kerber</name></json:item><json:item><name>A Atmaca</name></json:item></author><host><volume>30</volume><pages><last>34</last><first>29</first></pages><author></author><title>Onkologie</title><publicationDate>2007</publicationDate></host><title>Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>Jp Caussanel</name></json:item><json:item><name>F Levi</name></json:item><json:item><name>S Brienza</name></json:item></author><host><volume>82</volume><pages><last>1050</last><first>1046</first></pages><author></author><title>J Natl Cancer Inst</title><publicationDate>1990</publicationDate></host><title>Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Ab Miller</name></json:item><json:item><name>B Hoogstraten</name></json:item><json:item><name>M Staquet</name></json:item></author><host><volume>47</volume><pages><last>214</last><first>207</first></pages><author></author><title>Cancer</title><publicationDate>1981</publicationDate></host><title>Reporting results of cancer treatment</title><publicationDate>1981</publicationDate></json:item><json:item><author><json:item><name>Tr Fleming</name></json:item></author><host><volume>38</volume><pages><last>151</last><first>143</first></pages><author></author><title>Biometrics</title><publicationDate>1982</publicationDate></host><title>One-sample multiple testing procedure for phase II clinical trials</title><publicationDate>1982</publicationDate></json:item><json:item><author><json:item><name>Ad Roth</name></json:item><json:item><name>N Fazio</name></json:item><json:item><name>R Stupp</name></json:item></author><host><volume>25</volume><pages><last>3223</last><first>3217</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2007</publicationDate></host><title>Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>C Louvet</name></json:item><json:item><name>T Andre</name></json:item><json:item><name>Jm Tigaud</name></json:item></author><host><volume>20</volume><pages><last>4548</last><first>4543</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2002</publicationDate></host><title>Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients</title><publicationDate>2002</publicationDate></json:item><json:item><author><json:item><name>Dh Ilson</name></json:item></author><host><volume>25</volume><pages><last>3190</last><first>3188</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2007</publicationDate></host><title>Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>Ja Ajani</name></json:item><json:item><name>A Phan</name></json:item><json:item><name>L Ho</name></json:item></author><host><volume>25</volume><pages><last>4612</last><first>225</first></pages><author></author><title>J Clin Oncol</title><publicationDate>2007</publicationDate></host><title>Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric of gastroesophageal cancer</title><publicationDate>2007</publicationDate></json:item><json:item><author><json:item><name>S Lorenzen</name></json:item><json:item><name>M Hentrich</name></json:item><json:item><name>C Haberl</name></json:item></author><host><volume>18</volume><pages><last>1679</last><first>1673</first></pages><author></author><title>Ann Oncol</title><publicationDate>2007</publicationDate></host><title>Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial</title><publicationDate>2007</publicationDate></json:item></refBibs><genre><json:string>research-article</json:string></genre><host><volume>19</volume><publisherId><json:string>annonc</json:string></publisherId><pages><last>1887</last><first>1882</first></pages><issn><json:string>0923-7534</json:string></issn><issue>11</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1569-8041</json:string></eissn><title>Annals of Oncology</title></host><categories><wos><json:string>science</json:string><json:string>oncology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1093/annonc/mdn403</json:string></doi><id>DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0</id><score>0.2502757</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</p></availability><date>2008-07-31</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title><author xml:id="author-1" corresp="yes"><persName><forename type="first">S.-E.</forename><surname>Al-Batran</surname></persName><email>albatran@aol.com</email><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation></author><author xml:id="author-2"><persName><forename type="first">J. T.</forename><surname>Hartmann</surname></persName><affiliation>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</affiliation></author><author xml:id="author-3"><persName><forename type="first">R.</forename><surname>Hofheinz</surname></persName><affiliation>Department of Medicine III, Universittsklinikum Mannheim</affiliation></author><author xml:id="author-4"><persName><forename type="first">N.</forename><surname>Homann</surname></persName><affiliation>Department of Medicine I, University of Lbeck</affiliation></author><author xml:id="author-5"><persName><forename type="first">V.</forename><surname>Rethwisch</surname></persName><affiliation>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</affiliation></author><author xml:id="author-6"><persName><forename type="first">S.</forename><surname>Probst</surname></persName><affiliation>Department of Hematology and Oncology, Stdtische Kliniken, Bielefeld</affiliation></author><author xml:id="author-7"><persName><forename type="first">J.</forename><surname>Stoehlmacher</surname></persName><affiliation>Department of Internal Medicine I, Universittsklinikum Carl Gustav Carus, Dresden</affiliation></author><author xml:id="author-8"><persName><forename type="first">M. R.</forename><surname>Clemens</surname></persName><affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</affiliation></author><author xml:id="author-9"><persName><forename type="first">R.</forename><surname>Mahlberg</surname></persName><affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</affiliation></author><author xml:id="author-10"><persName><forename type="first">M.</forename><surname>Fritz</surname></persName><affiliation>Krankenhaus Bad Cannstatt, Stuttgart</affiliation></author><author xml:id="author-11"><persName><forename type="first">G.</forename><surname>Seipelt</surname></persName><affiliation>Gemeinschaftspraxis fr Hmatologie und Internistische Onkologie, Bad Soden</affiliation></author><author xml:id="author-12"><persName><forename type="first">M.</forename><surname>Sievert</surname></persName><affiliation>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</affiliation></author><author xml:id="author-13"><persName><forename type="first">C.</forename><surname>Pauligk</surname></persName><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation></author><author xml:id="author-14"><persName><forename type="first">A.</forename><surname>Atmaca</surname></persName><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation></author><author xml:id="author-15"><persName><forename type="first">E.</forename><surname>Jger</surname></persName><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation></author></analytic><monogr><title level="j">Annals of Oncology</title><idno type="pISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2008-07-31"></date><biblScope unit="volume">19</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1882">1882</biblScope><biblScope unit="page" to="1887">1887</biblScope></imprint></monogr><idno type="istex">DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0</idno><idno type="DOI">10.1093/annonc/mdn403</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008-07-31</date></creation><abstract><p>Background: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients and methods: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-h infusion in combination with docetaxel 50 mg/m2 (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered. Results: Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 2976) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only. Conclusions: Biweekly FLOT is active and has a favorable safety profile.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>original articles</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>docetaxel</term></item><item><term>esophageal</term></item><item><term>FLOT</term></item><item><term>gastric</term></item><item><term>oxaliplatin</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-07-31">Created</change><change when="2008-07-31">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-12-22">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">annonc</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-title>Annals of Oncology</journal-title><issn pub-type="epub">1569-8041</issn><issn pub-type="ppub">0923-7534</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/annonc/mdn403</article-id><article-categories><subj-group><subject>original articles</subject><subj-group><subject>gastrointestinal tumors</subject></subj-group></subj-group></article-categories><title-group><article-title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Al-Batran</surname><given-names>S.-E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hartmann</surname><given-names>J. T.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hofheinz</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Homann</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rethwisch</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Probst</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Stoehlmacher</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Clemens</surname><given-names>M. R.</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Mahlberg</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Fritz</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Seipelt</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Sievert</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Pauligk</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atmaca</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jäger</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt</aff><aff id="aff2"><label>2</label>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</aff><aff id="aff3"><label>3</label>Department of Medicine III, Universitätsklinikum Mannheim</aff><aff id="aff4"><label>4</label>Department of Medicine I, University of Lübeck</aff><aff id="aff5"><label>5</label>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</aff><aff id="aff6"><label>6</label>Department of Hematology and Oncology, Städtische Kliniken, Bielefeld</aff><aff id="aff7"><label>7</label>Department of Internal Medicine I, Universitätsklinikum Carl Gustav Carus, Dresden</aff><aff id="aff8"><label>8</label>Department of Medicine I, Mutterhaus der Borromäerinnen, Trier</aff><aff id="aff9"><label>9</label>Krankenhaus Bad Cannstatt, Stuttgart</aff><aff id="aff10"><label>10</label>Gemeinschaftspraxis für Hämatologie und Internistische Onkologie, Bad Soden</aff><aff id="aff11"><label>11</label>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</aff><author-notes><corresp id="cor1"><label>*</label><italic>Correspondence to:</italic> Dr S.-E. Al-Batran, Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt am Main, Germany. Tel: +496976013788; Fax: +496976013655; E-mail: <email>albatran@aol.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>11</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2008</year></pub-date><volume>19</volume><issue>11</issue><fpage>1882</fpage><lpage>1887</lpage><history><date date-type="received"><day>26</day><month>2</month><year>2008</year></date><date date-type="rev-recd"><day>2</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2008</copyright-year></permissions><abstract><p><bold>Background:</bold> The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen.</p><p><bold>Patients and methods:</bold> Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m<sup>2</sup>, leucovorin 200 mg/m<sup>2</sup>, and fluorouracil 2600 mg/m<sup>2</sup> as a 24-h infusion in combination with docetaxel 50 mg/m<sup>2</sup> (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered.</p><p><bold>Results:</bold> Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 29–76) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only.</p><p><bold>Conclusions:</bold> Biweekly FLOT is active and has a favorable safety profile.</p></abstract><kwd-group><kwd>docetaxel</kwd><kwd>esophageal</kwd><kwd>FLOT</kwd><kwd>gastric</kwd><kwd>oxaliplatin</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">S.-E.</namePart><namePart type="family">Al-Batran</namePart><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation><affiliation>E-mail: albatran@aol.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. T.</namePart><namePart type="family">Hartmann</namePart><affiliation>Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology South West Cancer Center, Eberhard-Karls-University, Tuebingen</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Hofheinz</namePart><affiliation>Department of Medicine III, Universittsklinikum Mannheim</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Homann</namePart><affiliation>Department of Medicine I, University of Lbeck</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Rethwisch</namePart><affiliation>Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Probst</namePart><affiliation>Department of Hematology and Oncology, Stdtische Kliniken, Bielefeld</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Stoehlmacher</namePart><affiliation>Department of Internal Medicine I, Universittsklinikum Carl Gustav Carus, Dresden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. R.</namePart><namePart type="family">Clemens</namePart><affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Mahlberg</namePart><affiliation>Department of Medicine I, Mutterhaus der Borromerinnen, Trier</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Fritz</namePart><affiliation>Krankenhaus Bad Cannstatt, Stuttgart</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Seipelt</namePart><affiliation>Gemeinschaftspraxis fr Hmatologie und Internistische Onkologie, Bad Soden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Sievert</namePart><affiliation>Medical Oncology, Sanofi Aventis Deutschland GmbH, Berlin, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Pauligk</namePart><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Atmaca</namePart><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Jger</namePart><affiliation>Klinik fr Onkologie und Hmatologie, Krankenhaus Nordwest, Frankfurt</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>original articles</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2008-07-31</dateIssued><dateCreated encoding="w3cdtf">2008-07-31</dateCreated><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Background: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients and methods: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2600 mg/m2 as a 24-h infusion in combination with docetaxel 50 mg/m2 (FLOT) on day 1 every 2 weeks. Prophylactic growth factors were not administered. Results: Fifty-nine patients were enrolled; 54 received treatment. Patients had a median age of 60 years (range 2976) and most (93%) of them had metastatic disease. Objective responses were observed in 57.7% of patients with a median time to treatment response of 1.54 months. Median progression-free survival (PFS) and overall survival were 5.2 and 11.1 months, respectively. Twenty-five percent of patients experienced prolonged (>12 months) PFS. Frequent (>10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in 8 (14.8%), and fatigue in 6 (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients, only. Conclusions: Biweekly FLOT is active and has a favorable safety profile.</abstract><subject><genre>keywords</genre><topic>docetaxel</topic><topic>esophageal</topic><topic>FLOT</topic><topic>gastric</topic><topic>oxaliplatin</topic></subject><relatedItem type="host"><titleInfo><title>Annals of Oncology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0923-7534</identifier><identifier type="eISSN">1569-8041</identifier><identifier type="PublisherID">annonc</identifier><identifier type="PublisherID-hwp">annonc</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1882</start><end>1887</end></extent></part></relatedItem><identifier type="istex">DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0</identifier><identifier type="DOI">10.1093/annonc/mdn403</identifier><accessCondition type="use and reproduction" contentType="copyright">The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><extension>gif</extension><original>true</original><mimetype>image/gif</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/covers/gif</uri></json:item><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/covers/tiff</uri></json:item></covers><annexes><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/annexes/jpeg</uri></json:item><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0/annexes/pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001956 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001956 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DD9BE3406436815243DA8F1A3BC8720CC5B4E0E0
|texte= Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
}}
| This area was generated with Dilib version V0.6.31. |  |